The DOI matches its Crossref record; 168 of the 168 references it cites were found in a registry or an index.
Targeting ERK1/2 protein-serine/threonine kinases in human cancers
Abstract
ERK1 and ERK2 are key protein kinases that contribute to the Ras-Raf-MEK-ERK MAP kinase signalling module. This pathway participates in the control of numerous processes including apoptosis, cell proliferation, the immune response, nervous system function, and RNA synthesis and processing. MEK1/2 activate human ERK1/2 by first catalyzing the phosphorylation of Y204/187 and then T202/185, both residues of which occur within the activation segment. The phosphorylation of both residues is required for enzyme activation. The only Raf substrates are MEK1/2 and the only MEK1/2 substrates are ERK1/2. In contrast, ERK1/2 catalyze the phosphorylation of many cytoplasmic and nuclear substrates including transcription factors and regulatory molecules. The linear MAP kinase pathway branches extensively at the ERK1/2 node. ERK1/2 are proline-directed kinases that preferentially catalyze the phosphorylation of substrates containing a PxS/TP sequence. The dephosphorylation and inactivation of ERK1/2 is catalyzed by dual specificity phosphatases, protein-tyrosine specific phosphatases, and protein-serine/threonine phosphatases. The combined functions of kinases and phosphatases make the overall process reversible. To provide an idea of the complexities involved in these reactions, somatic cell cycle progression involves the strict timing of more than 32,000 phosphorylation and dephosphorylation events as determined by mass spectrometry. The MAP kinase cascade is perhaps the most important oncogenic driver of human cancers and the blockade of this signalling module by targeted inhibitors is an important anti-tumor strategy. Although numerous cancers are driven by MAP kinase pathway activation, thus far the only orally effective approved drugs that target this signaling module are used for the treatment of BRAF-mutant melanomas. The best treatments include the combination of B-Raf and MEK inhibitors (dabrafenib and trametinib, encorafenib and binimetinib, vemurafenib and cobimetanib). However, resistance to these antagonists occurs within one year and additional treatment options are necessary. Owing to the large variety of malignancies that are driven by dysregulation of the MAP kinase pathway, additional tumor types should be amenable to MAP kinase pathway inhibitor therapy. In addition to new B-Raf and MEK inhibitors, the addition of ERK inhibitors should prove helpful. Ulixertinib, MK-8353, and GDC-0994 are orally effective, potent, and specific inhibitors of ERK1/2 that are in early clinical trials for the treatment of various advanced/metastatic solid tumors. These agents are effective against cell lines that are resistant to B-Raf and MEK1/2 inhibitor therapy. Although MK-8353 does not directly inhibit MEK1/2, it decreases the phosphorylation of ERK1/2 as well as the phosphorylation of RSK, an ERK1/2 substrate. The decrease in RSK phosphorylation appears to be a result of ERK inhibition and the decrease in ERK1/2 phosphorylation is related to the inability of MEK to catalyze the phosphorylation of the ERK-MK-8353 complex; these decreases characterize the ERK dual mechanism inhibition paradigm. Additional work will be required to determine whether ERK inhibitors will be successful in the clinic and are able to forestall the development of drug resistance of the MAP kinase pathway.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
The protein kinase complement of the human genome
Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002) · Science · doi:10.1126/science.1075762 · Cited by 8,145
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Cavallo, G., Metrangolo, P., Milani, R., Pilati, T., Priimagi, A., Resnati, G., & Terraneo, G. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00484 · Cited by 4,035
Mitogen-Activated Protein (MAP) Kinase Pathways: Regulation and Physiological Functions*
Pearson, G., Robinson, F., Beers Gibson, T., Xu, B.-E., Karandikar, M., Berman, K., & Cobb, M. H. (2001) · Endocrine Reviews · doi:10.1210/edrv.22.2.0428 · Cited by 4,034
Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases
Cargnello, M., & Roux, P. P. (2011) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00031-10 · Cited by 3,274
Genomic classification of cutaneous melanoma
Akbani, R., Akdemir, K. C., Aksoy, B. A., Albert, M., Ally, A., Amin, S. B., Arachchi, H., Arora, A., Auman, J. T., Ayala, B., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.044 · Cited by 3,151
MAP kinase signalling pathways in cancer
Dhillon, A. S., Hagan, S., Rath, O., & Kolch, W. (2007) · Oncogene · doi:10.1038/sj.onc.1210421 · Cited by 2,995
Hauschild, A., Grob, J.-J., Demidov, L. V., Jouary, T., Gutzmer, R., Millward, M., Rutkowski, P., Blank, C. U., Miller, W. H., Kaempgen, E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60868-x · Cited by 2,989
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
A landscape of driver mutations in melanoma
Hodis, E., Watson, I. R., Kryukov, G. V., Arold, S. T., Imielinski, M., Theurillat, J.-P., Nickerson, E., Auclair, D., Li, L., Place, C., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.024 · Cited by 2,610
Hunter, T. (2000) · Cell · doi:10.1016/s0092-8674(00)81688-8 · Cited by 2,586
Hanks, S. K., & Hunter, T. R. (1995) · PubMed · Cited by 2,518
The influence of drug-like concepts on decision-making in medicinal chemistry
Leeson, P. D., & Springthorpe, B. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2445 · Cited by 2,403
The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification 1
Hanks, S. K., & Hunter, T. (1995) · The FASEB Journal · doi:10.1096/fasebj.9.8.7768349 · Cited by 2,318
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M., Demidov, L. V., Hassel, J. C., Rutkowski, P., Mohr, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203421 · Cited by 2,160
The mitogen-activated protein kinase signal transduction pathway
Davis, R. J. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)82362-6 · Cited by 2,139
Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma
Larkin, J., Ascierto, P. A., Dréno, B., Atkinson, V., Liszkay, G., Maio, M., Mandalà, M., Demidov, L., Stroyakovskiy, D., Thomas, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408868 · Cited by 2,068
RAS Proteins and Their Regulators in Human Disease
Simanshu, D. K., Nissley, D. V., & McCormick, F. (2017) · Cell · doi:10.1016/j.cell.2017.06.009 · Cited by 1,943 · cited 18×
“The Ras-Raf-MEK-ERK MAP kinase signal transduction module is one of the most prevalent oncogenic pathways in human cancers [8–12,163].”
BackgroundInfluentialRAS oncogenes: the first 30 years
Malumbres, M., & Barbacid, M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1097 · Cited by 1,902
Protein Tyrosine Phosphatases in the Human Genome
Alonso, A., Sasin, J., Bottini, N., Friedberg, I., Friedberg, I., Osterman, A., Godzik, A., Hunter, T., Dixon, J., & Mustelin, T. (2004) · Cell · doi:10.1016/j.cell.2004.05.018 · Cited by 1,886
Ligand efficiency: a useful metric for lead selection
Hopkins, A. L., Groom, C. R., & Alex, A. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03069-7 · Cited by 1,846
RAS oncogenes: weaving a tumorigenic web
Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3106 · Cited by 1,789
Knighton, D. R., Zheng, J., Ten Eyck, L. F., Ashford, V. A., Xuong, N.-H., Taylor, S. S., & Sowadski, J. M. (1991) · Science · doi:10.1126/science.1862342 · Cited by 1,759
ERK1/2 MAP kinases: Structure, function, and regulation
Roskoski, R. (2012) · Pharmacological Research · doi:10.1016/j.phrs.2012.04.005 · Cited by 1,650
Self-citationMitogen-Activated Protein Kinases: Specific Messages from Ubiquitous Messengers
Schaeffer, H. J., & Weber, M. J. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.4.2435 · Cited by 1,600 · cited 1×
“Enzymes such as MEK1/2, which catalyze the phosphorylation of tyrosine and then threonine in the activation segment of ERK1/2, make up a small group of so-called dual-specificity protein kinases [6,7].”
BackgroundThe JNK signal transduction pathway
Weston, C. (2002) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(01)00258-1 · Cited by 1,528
Differential regulation and properties of MAPKs
Raman, M., Chen, W., & Cobb, M. H. (2007) · Oncogene · doi:10.1038/sj.onc.1210392 · Cited by 1,430 · cited 1×
“KSR1/2 are impaired protein kinases (but not kinase dead) that are able to function as scaffolds that assemble Raf, MEK, and ERK to increase signaling efficiency [21].”
BackgroundThe ErbB/HER family of protein-tyrosine kinases and cancer
Roskoski, R. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2013.11.002 · Cited by 1,353
Self-citationTargeted agents and immunotherapies: optimizing outcomes in melanoma
Luke, J. J., Flaherty, K. T., Ribas, A., & Long, G. V. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.43 · Cited by 1,254
The role of ligand efficiency metrics in drug discovery
Hopkins, A. L., Keserü, G. M., Leeson, P. D., Rees, D. C., & Reynolds, C. H. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4163 · Cited by 1,181
Targeting RAS–ERK signalling in cancer: promises and challenges
Samatar, A. A., & Poulikakos, P. I. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4281 · Cited by 1,163
Roth, B. L., Sheffler, D. J., & Kroeze, W. K. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1346 · Cited by 1,155
Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF
Jacobs, J. J. L., Scheijen, B., Voncken, J.-W., Kieboom, K., Berns, A., & van Lohuizen, M. (1999) · Genes & Development · doi:10.1101/gad.13.20.2678 · Cited by 1,065
Anderson, N. G., Maller, J. L., Tonks, N. K., & Sturgill, T. W. (1990) · Nature · doi:10.1038/343651a0 · Cited by 1,063
Dummer, R., Ascierto, P. A., Gogas, H. J., Arance, A., Mandala, M., Liszkay, G., Garbe, C., Schadendorf, D., Krajsova, I., Gutzmer, R., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30142-6 · Cited by 1,037
The JNK signal transduction pathway
Weston, C. R., & Davis, R. J. (2007) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2007.02.001 · Cited by 1,021
Kinase inhibitors: the road ahead
Ferguson, F. M., & Gray, N. S. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.21 · Cited by 1,009
The MAPK cascades: Signaling components, nuclear roles and mechanisms of nuclear translocation
Plotnikov, A., Zehorai, E., Procaccia, S., & Seger, R. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2010.12.012 · Cited by 986
Knighton, D. R., Zheng, J., Ten Eyck, L. F., Xuong, N.-H., Taylor, S. S., & Sowadski, J. M. (1991) · Science · doi:10.1126/science.1862343 · Cited by 960
Protein kinases: evolution of dynamic regulatory proteins
Taylor, S. S., & Kornev, A. P. (2011) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2010.09.006 · Cited by 945
Roskoski, R. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2015.10.021 · Cited by 886
Self-citationKemp, B. E., Graves, D. J., Benjamini, E., & Krebs, E. G. (1977) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)40137-2 · Cited by 835
Stephen, A. G., Esposito, D., Bagni, R. K., & McCormick, F. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.017 · Cited by 795
Regulation of MAP Kinase Signaling Modules by Scaffold Proteins in Mammals
Morrison, D. K., & Davis, R. J. (2003) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.19.111401.091942 · Cited by 786
Kornev, A. P., Haste, N. M., Taylor, S. S., & Ten Eyck, L. F. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607656103 · Cited by 762
Activation mechanism of the MAP kinase ERK2 by dual phosphorylation
Canagarajah, B. J., Khokhlatchev, A., Cobb, M. H., & Goldsmith, E. J. (1997) · Cell · doi:10.1016/s0092-8674(00)80351-7 · Cited by 729
The drug–target residence time model: a 10-year retrospective
Copeland, R. A. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.18 · Cited by 722
Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring BRAF Mutations
Paik, P. K., Arcila, M. E., Fara, M., Sima, C. S., Miller, V. A., Kris, M. G., Ladanyi, M., & Riely, G. J. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.1280 · Cited by 691
Morris, E. J., Jha, S., Restaino, C. R., Dayananth, P., Zhu, H., Cooper, A., Carr, D., Deng, Y., Jin, W., Black, S., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0070 · Cited by 676
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis
Eisen, T., Ahmad, T., Flaherty, K. T., Gore, M., Kaye, S., Marais, R., Gibbens, I., Hackett, S., James, M., Schuchter, L. M., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603291 · Cited by 644
Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design
Ostrem, J. M. L., & Shokat, K. M. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.139 · Cited by 641
Lipinski, C. A. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.029 · Cited by 609
Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors
Roskoski, R. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.01.003 · Cited by 607
Self-citationAtomic structure of the MAP kinase ERK2 at 2.3 A resolution
Zhang, F., Strand, A., Robbins, D., Cobb, M. H., & Goldsmith, E. J. (1994) · Nature · doi:10.1038/367704a0 · Cited by 592
THE ENZYMATIC PHOSPHORYLATION OF PROTEINS
Burnett, G., & Kennedy, E. P. (1954) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)71184-8 · Cited by 582
Clinical Implication of Hot Spot BRAF Mutation, V599E, in Papillary Thyroid Cancers
Namba, H., Nakashima, M., Hayashi, T., Hayashida, N., Maeda, S., Rogounovitch, T. I., Ohtsuru, A., Saenko, V. A., Kanematsu, T., & Yamashita, S. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030305 · Cited by 533
A historical overview of protein kinases and their targeted small molecule inhibitors
Roskoski, R. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.07.010 · Cited by 526
Self-citationThrough the “Gatekeeper Door”: Exploiting the Active Kinase Conformation
Zuccotto, F., Ardini, E., Casale, E., & Angiolini, M. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901443h · Cited by 518
Protein phosphatase 2A regulatory subunits and cancer
Eichhorn, P. J. A., Creyghton, M. P., & Bernards, R. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2008.05.005 · Cited by 513
Liao, J. J.-L. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm0608107 · Cited by 507
Roskoski, R. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2018.11.014 · Cited by 487
Self-citationKim, K. B., Kefford, R., Pavlick, A. C., Infante, J. R., Ribas, A., Sosman, J. A., Fecher, L. A., Millward, M., McArthur, G. A., Hwu, P., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.5966 · Cited by 477
A helix scaffold for the assembly of active protein kinases
Kornev, A. P., Taylor, S. S., & Ten Eyck, L. F. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0807988105 · Cited by 442
Jacobs, D., Glossip, D., Xing, H., Muslin, A. J., & Kornfeld, K. (1999) · Genes & Development · doi:10.1101/gad.13.2.163 · Cited by 439
Zhao, Z., Wu, H., Wang, L., Liu, Y., Knapp, S., Liu, Q., & Gray, N. S. (2014) · ACS Chemical Biology · doi:10.1021/cb500129t · Cited by 433
Targeting ERK, an Achilles' Heel of the MAPK pathway, in cancer therapy
Liu, F., Yang, X., Geng, M., & Huang, M. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.01.008 · Cited by 432
Sullivan, R. J., Infante, J. R., Janku, F., Wong, D. J. L., Sosman, J. A., Keedy, V., Patel, M. R., Shapiro, G. I., Mier, J. W., Tolcher, A. W., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1119 · Cited by 426
The clinical development of MEK inhibitors
Zhao, Y., & Adjei, A. A. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.83 · Cited by 400
Dynamics of cAMP-Dependent Protein Kinase
Johnson, D. A., Akamine, P., Radzio-Andzelm, E., Madhusudan, & Taylor, S. S. (2001) · Chemical Reviews · doi:10.1021/cr000226k · Cited by 393
Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs
Roskoski, R. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2018.11.035 · Cited by 393
Self-citationThe Evolution of Protein Kinase Inhibitors from Antagonists to Agonists of Cellular Signaling
Dar, A. C., & Shokat, K. M. (2011) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-090308-173656 · Cited by 388
Inhibition of Ras for Cancer Treatment: The Search Continues
Baines, A. T., Xu, D., & Der, C. J. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.121 · Cited by 382
Kinase Drug Discovery – What’s Next in the Field?
Cohen, P., & Alessi, D. R. (2013) · ACS Chemical Biology · doi:10.1021/cb300610s · Cited by 377
RAF protein-serine/threonine kinases: Structure and regulation
Roskoski, R. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.07.092 · Cited by 376
Self-citationJanus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases
Roskoski, R. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.07.038 · Cited by 373
Self-citationCardarella, S., Ogino, A., Nishino, M., Butaney, M., Shen, J., Lydon, C., Yeap, B. Y., Sholl, L. M., Johnson, B. E., & Jänne, P. A. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0657 · Cited by 372
Ten things you should know about protein kinases: IUPHAR R eview 14
Fabbro, D., Cowan‐Jacob, S. W., & Moebitz, H. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13096 · Cited by 347
Mechanistic Studies of the Dual Phosphorylation of Mitogen-activated Protein Kinase
Ferrell, J. E., & Bhatt, R. R. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.30.19008 · Cited by 344
Jones, J. C., Renfro, L. A., Al-Shamsi, H. O., Schrock, A. B., Rankin, A., Zhang, B. Y., Kasi, P. M., Voss, J. S., Leal, A. D., Sun, J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.4394 · Cited by 339
Gibbs, C. S., & Zoller, M. J. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)31532-1 · Cited by 334
Anaplastic lymphoma kinase (ALK): Structure, oncogenic activation, and pharmacological inhibition
Roskoski, R. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2012.11.007 · Cited by 303
Self-citationKLIFS: A Knowledge-Based Structural Database To Navigate Kinase–Ligand Interaction Space
van Linden, O. P. J., Kooistra, A. J., Leurs, R., de Esch, I. J. P., & de Graaf, C. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm400378w · Cited by 298
Protein Kinases and Phosphatases in the Control of Cell Fate
Bononi, A., Agnoletto, C., De Marchi, E., Marchi, S., Patergnani, S., Bonora, M., Giorgi, C., Missiroli, S., Poletti, F., Rimessi, A., et al. (2011) · Enzyme Research · doi:10.4061/2011/329098 · Cited by 285
Dynamics-Driven Allostery in Protein Kinases
Kornev, A. P., & Taylor, S. S. (2015) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2015.09.002 · Cited by 284
MEK1/2 dual-specificity protein kinases: Structure and regulation
Roskoski, R. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.11.145 · Cited by 276
Self-citationGlycogen synthase kinase-3 beta (GSK-3β) signaling: Implications for Parkinson's disease
Golpich, M., Amini, E., Hemmati, F., Ibrahim, N. M., Rahmani, B., Mohamed, Z., Raymond, A. A., Dargahi, L., Ghasemi, R., & Ahmadiani, A. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.03.010 · Cited by 276
Madhusudan, Trafny, E. A., Xuong, N., Adams, J. A., Eyck, L. F. T., Taylor, S. S., & Sowadski, J. M. (1994) · Protein Science · doi:10.1002/pro.5560030203 · Cited by 274
Defining the conserved internal architecture of a protein kinase
Kornev, A. P., & Taylor, S. S. (2010) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2009.10.017 · Cited by 266
New Paradigms in Anticancer Therapy: Targeting Multiple Signaling Pathways With Kinase Inhibitors
FAIVRE, S., DJELLOUL, S., & RAYMOND, E. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.04.005 · Cited by 264
Roskoski, R. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.03.010 · Cited by 260
Self-citationVijayan, R. S. K., He, P., Modi, V., Duong-Ly, K. C., Ma, H., Peterson, J. R., Dunbrack, R. L., & Levy, R. M. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501603h · Cited by 245
Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs
Roskoski, R. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.03.012 · Cited by 237
Self-citationEvolution of the eukaryotic protein kinases as dynamic molecular switches
Taylor, S. S., Keshwani, M. M., Steichen, J. M., & Kornev, A. P. (2012) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2012.0054 · Cited by 233
Germann, U. A., Furey, B. F., Markland, W., Hoover, R. R., Aronov, A. M., Roix, J. J., Hale, M., Boucher, D. M., Sorrell, D. A., Martinez-Botella, G., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0456 · Cited by 233
The dual-specificity MAP kinase phosphatases: critical roles in development and cancer
Bermudez, O., Pagès, G., & Gimond, C. (2010) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00347.2009 · Cited by 230
ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors
Roskoski, R. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2014.06.001 · Cited by 218
Self-citationDeciphering the Structural Basis of Eukaryotic Protein Kinase Regulation
Meharena, H. S., Chang, P., Keshwani, M. M., Oruganty, K., Nene, A. K., Kannan, N., Taylor, S. S., & Kornev, A. P. (2013) · PLoS Biology · doi:10.1371/journal.pbio.1001680 · Cited by 208
AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective: Miniperspective
Myers, S. H., Brunton, V. G., & Unciti-Broceta, A. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01273 · Cited by 203
Protein kinase biochemistry and drug discovery
Schwartz, P. A., & Murray, B. W. (2011) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2011.07.004 · Cited by 201
PKIDB: A Curated, Annotated and Updated Database of Protein Kinase Inhibitors in Clinical Trials
Carles, F., Bourg, S., Meyer, C., & Bonnet, P. (2018) · Molecules · doi:10.3390/molecules23040908 · Cited by 197
Targeting oncogenic Raf protein-serine/threonine kinases in human cancers
Roskoski, R. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.08.013 · Cited by 194
Self-citationTargeting Rho and Rho-kinase in the treatment of cardiovascular disease
Budzyn, K., Marley, P. D., & Sobey, C. G. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.12.002 · Cited by 191
The Activating Dual Phosphorylation of MAPK by MEK Is Nonprocessive
Burack, W. R., & Sturgill, T. W. (1997) · Biochemistry · doi:10.1021/bi970535d · Cited by 189
Approaches to discover non-ATP site kinase inhibitors
Gavrin, L. K., & Saiah, E. (2013) · MedChemComm · doi:10.1039/c2md20180a · Cited by 184
New Directions in Targeting Protein Kinases: Focusing Upon True Allosteric and Bivalent Inhibitors
Lamba, V., & Ghosh, I. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212800672813 · Cited by 182
Selective p38α Inhibitors Clinically Evaluated for the Treatment of Chronic Inflammatory Disorders
Goldstein, D. M., Kuglstatter, A., Lou, Y., & Soth, M. J. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm9012906 · Cited by 180
Ünal, E. B., Uhlitz, F., & Blüthgen, N. (2017) · FEBS Letters · doi:10.1002/1873-3468.12740 · Cited by 180
Molecular inflation, attrition and the rule of five
Leeson, P. D. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.01.018 · Cited by 179
RAS-mediated oncogenic signaling pathways in human malignancies
Khan, A. Q., Kuttikrishnan, S., Siveen, K. S., Prabhu, K. S., Shanmugakonar, M., Al- Naemi, H. A., Haris, M., Dermime, S., & Uddin, S. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.03.001 · Cited by 179
Hermiston, M. L., Zikherman, J., & Zhu, J. W. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00752.x · Cited by 170
Roskoski, R. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.01.021 · Cited by 170
Self-citationThe JIP family of MAPK scaffold proteins
Whitmarsh, A. J. (2006) · Biochemical Society Transactions · doi:10.1042/bst0340828 · Cited by 168
Nygaard, H. B., Wagner, A. F., Bowen, G. S., Good, S. P., MacAvoy, M. G., Strittmatter, K. A., Kaufman, A. C., Rosenberg, B. J., Sekine-Konno, T., Varma, P., et al. (2015) · Alzheimer's Research & Therapy · doi:10.1186/s13195-015-0119-0 · Cited by 165
Moschos, S. J., Sullivan, R. J., Hwu, W., Ramanathan, R. K., Adjei, A. A., Fong, P. C. C., Shapira‐Frommer, R., Tawbi, H. A.-H., Rubino, J., Rush, T. S., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.92352 · Cited by 163
ERK1/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1/2-ERK1/2 pathway
Kidger, A. M., Sipthorp, J., & Cook, S. J. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.02.007 · Cited by 160
Blake, J. F., Burkard, M., Chan, J., Chen, H., Chou, K.-J., Diaz, D., Dudley, D. A., Gaudino, J. J., Gould, S. E., Grina, J. A., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00389 · Cited by 159
Ordered phosphorylation of p42mapk by MAP kinase kinase
Haystead, T., Dent, P., Wu, J., Haystead, C. M. M., & Sturgill, T. W. (1992) · FEBS Letters · doi:10.1016/0014-5793(92)80828-5 · Cited by 156
A molecular gate which controls unnatural ATP analogue recognition by the tyrosine kinase v-Src
Liu, Y., Shah, K., Yang, F., Witucki, L. A., & Shokat, K. M. (1998) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(98)00099-6 · Cited by 156
The reactivity-driven biochemical mechanism of covalent KRASG12C inhibitors
Hansen, R., Peters, U., Babbar, A., Chen, Y., Feng, J., Janes, M. R., Li, L.-S., Ren, P., Liu, Y., & Zarrinkar, P. P. (2018) · Nature Structural & Molecular Biology · doi:10.1038/s41594-018-0061-5 · Cited by 153
Pharmacological targeting of RAS: recent success with direct inhibitors
O’Bryan, J. P. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2018.10.021 · Cited by 153
Roskoski, R. J. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.04.022 · Cited by 138
Self-citationHanks, S. K. (1991) · Current Opinion in Structural Biology · doi:10.1016/0959-440x(91)90035-r · Cited by 136
Sequence and structural analysis of kinase ATP pocket residues
Vulpetti, A., & Bosotti, R. (2004) · Il Farmaco · doi:10.1016/j.farmac.2004.05.010 · Cited by 133
Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers
Roskoski, R. J. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.01.007 · Cited by 133
Self-citationImmunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy
Kuske, M., Westphal, D., Wehner, R., Schmitz, M., Beissert, S., Praetorius, C., & Meier, F. E. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.08.019 · Cited by 133
Total ERK1/2 activity regulates cell proliferation
LeFloch, R., Pouysségur, J., & Lenormand, P. (2009) · Cell Cycle · doi:10.4161/cc.8.5.7734 · Cited by 121
Roskoski, R. J. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.12.009 · Cited by 119
Self-citationA dynamic hydrophobic core orchestrates allostery in protein kinases
Kim, J., Ahuja, L. G., Chao, F.-A., Xia, Y., McClendon, C. L., Kornev, A. P., Taylor, S. S., & Veglia, G. (2017) · Science Advances · doi:10.1126/sciadv.1600663 · Cited by 118
Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers
Roskoski, R. J., & Sadeghi‐Nejad, A. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.12.021 · Cited by 118
Self-citationGuidelines for preparing color figures for everyone including the colorblind
Roskoski, R. J. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.02.005 · Cited by 112
Self-citationLigand efficiency metrics in drug discovery: the pros and cons from a practical perspective
Cavalluzzi, M. M., Mangiatordi, G. F., Nicolotti, O., & Lentini, G. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1365056 · Cited by 106
Redefining the Protein Kinase Conformational Space with Machine Learning
Ung, P. M. U., Rahman, R., & Schlessinger, A. (2018) · Cell chemical biology · doi:10.1016/j.chembiol.2018.05.002 · Cited by 104
Sequence Determinants of a Specific Inactive Protein Kinase Conformation
Hari, S. B., Merritt, E. A., & Maly, D. J. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.05.005 · Cited by 97
Structure-based Virtual Screening Approaches in Kinase-directed Drug Discovery
Bajusz, D., Ferenczy, G. G., & Keserű, G. M. (2017) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026617666170224121313 · Cited by 88
Approved and Experimental Small‐Molecule Oncology Kinase Inhibitor Drugs: A Mid‐2016 Overview
Fischer, P. M. (2016) · Medicinal Research Reviews · doi:10.1002/med.21409 · Cited by 84
The Jakinibs in systemic lupus erythematosus: progress and prospects
Mok, C. C. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1551358 · Cited by 84
Participation of ADP Dissociation in the Rate-Determining Step in cAMP-Dependent Protein Kinase
Zhou, J., & Adams, J. A. (1997) · Biochemistry · doi:10.1021/bi971438n · Cited by 83
Palomo, V., Pérez, D. I., Roca, C., Anderson, C. J., Rodríguez‐Muela, N., Pérez, C., Morales-Garcia, J. A., Reyes, J. A., Campillo, N. E., Pérez‐Castillo, A., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00395 · Cited by 82
Roskoski, R. J. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.04.020 · Cited by 80
Self-citationKwarcinski, F. E., Brandvold, K. R., Phadke, S., Beleh, O. M., Johnson, T. K., Meagher, J. L., Seeliger, M. A., Stuckey, J. A., & Soellner, M. B. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.5b01018 · Cited by 75
ERK Mutations and Amplification Confer Resistance to ERK-Inhibitor Therapy
Jaiswal, B. S., Durinck, S., Stawiski, E. W., Yin, J., Wang, W., Lin, E., Moffat, J. G., Martin, S. E., Modrusan, Z. D., & Seshagiri, S. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3674 · Cited by 75
Joussen, A. M., Wolf, S., Kaiser, P. K., Boyer, D. S., Schmelter, T., Sandbrink, R., Zeitz, O., Deeg, G., Richter, A., Zimmermann, T., et al. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13794 · Cited by 66
Role of protein phosphatases in the cancer microenvironment
Ruvolo, P. P. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2018.07.006 · Cited by 64
Heightman, T. D., Berdini, V., Braithwaite, H. E., Buck, I. M., Cassidy, M. A., Castro, J., Courtin, A., Day, J. E. H., East, C., Fazal, L., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00421 · Cited by 63
Dual Leucine Zipper Kinase Inhibitors for the Treatment of Neurodegeneration
Siu, M., Ghosh, A. S., & Lewcock, J. W. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00370 · Cited by 61
Tao, L., Zhu, F., Xu, F., Chen, Z., Jiang, Y., & Chen, Y. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.09.019 · Cited by 56
Precision medicine review: rare driver mutations and their biophysical classification
Nussinov, R., Jang, H., Tsai, C., & Cheng, F. (2019) · Biophysical Reviews · doi:10.1007/s12551-018-0496-2 · Cited by 56
MK-8353: Discovery of an Orally Bioavailable Dual Mechanism ERK Inhibitor for Oncology
Boga, S. B., Deng, Y., Zhu, L. W., Yang, N., Cooper, A. B., Shipps, G. W., Doll, R. J., Shih, N., Zhu, H. Y. H., Sun, R., et al. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00220 · Cited by 54
Tau Tubulin Kinase 1 (TTBK1), a new player in the fight against neurodegenerative diseases
Nozal, V., & Martínez, A. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.10.030 · Cited by 51
CAR-T cells and combination therapies: What’s next in the immunotherapy revolution?
Ramello, M. C., Haura, E. B., & Abate‐Daga, D. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.11.035 · Cited by 45
Smith, G. F. (2009) · Progress in medicinal chemistry · doi:10.1016/s0079-6468(09)04801-2 · Cited by 42
Crystal structure of ERK2 G169D mutant
Yin, J., Jaiswal, B. S., & Wang, W. (2018) · Worldwide Protein Data Bank · doi:10.2210/pdb6d5y/pdb · Cited by 42
Wan, S., Bhati, A. P., Skerratt, S. E., Omoto, K., Shanmugasundaram, V., Bagal, S. K., & Coveney, P. V. (2017) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6b00780 · Cited by 38
Aronchik, I., Dai, Y., Labenski, M., Barnes, C., Jones, T., Qiao, L., Beebe, L., Malek, M., Elis, W., Shi, T., et al. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0554 · Cited by 37
Combination Therapies for Melanoma: A New Standard of Care?
Smalley, K. S. M., Eroglu, Z., & Sondak, V. K. (2016) · American Journal of Clinical Dermatology · doi:10.1007/s40257-016-0174-8 · Cited by 34
Eidam, H. S., Russell, J. P., Raha, K., DeMartino, M. P., Qin, D., Guan, H., Zhang, Z., Zhen, G., Yu, H., Wu, C., et al. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00035 · Cited by 34
Frame, M. C., & Roskoski, R. J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-809633-8.07199-5 · Cited by 32
Self-citationKinase-Centric Computational Drug Development
Kooistra, A. J., & Volkamer, A. (2017) · Annual reports in medicinal chemistry · doi:10.1016/bs.armc.2017.08.001 · Cited by 29
Thermodynamic Proxies to Compensate for Biases in Drug Discovery Methods
Ekins, S., Litterman, N. K., Lipinski, C. A., & Bunin, B. A. (2015) · Pharmaceutical Research · doi:10.1007/s11095-015-1779-y · Cited by 19
Bivalent Inhibitors of c-Src Tyrosine Kinase That Bind a Regulatory Domain
Johnson, T. K., & Soellner, M. B. (2016) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00243 · Cited by 19
Glaucoma Drugs in the Pipeline
Kaufman, P. L., Mohr, M., Riccomini, S. P., & Rasmussen, C. A. (2018) · Asia-Pacific Journal of Ophthalmology · doi:10.22608/apo.2018298 · Cited by 18
Pharmacological strategies to target oncogenic KRAS signaling in pancreatic cancer
Chuang, H.-C., Huang, P.-H., Kulp, S. K., & Chen, C. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.01.006 · Cited by 17
SnapShot: Phosphoregulation of Mitosis
Burgess, A., Vuong, J., Rogers, S., Malumbres, M., & O’Donoghue, S. I. (2017) · Cell · doi:10.1016/j.cell.2017.06.003 · Cited by 14
Let K-Ras activate its own inhibitor
Statsyuk, A. V. (2018) · Nature Structural & Molecular Biology · doi:10.1038/s41594-018-0066-0 · Cited by 9
Cited by
ERK/MAPK signalling pathway and tumorigenesis (Review)
Guo, Y., Pan, W., Liu, S., Shen, Z., Xu, Y., & Hu, L. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.8454 · Cited by 1,475
Targeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity
Lee, S., Rauch, J., & Kolch, W. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21031102 · Cited by 799
Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update
Roskoski, R. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2019.104609 · Cited by 559
Self-citationProperties of FDA-approved small molecule protein kinase inhibitors
Roskoski, R. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.03.006 · Cited by 554
Self-citationFluorine‐Containing Drugs Approved by the FDA in 2018
Mei, H., Han, J., Fustero, S., Medio‐Simon, M., Sedgwick, D. M., Santi, C., Ruzziconi, R., & Soloshonok, V. A. (2019) · Chemistry – A European Journal · doi:10.1002/chem.201901840 · Cited by 454
Metadata
- Authors
- Roskoski, R.
- Venue
- Pharmacological Research
- Publisher
- Elsevier BV
- Published
- 2019-04
- Volume
- 142
- Pages
- 151-168
- ISSN
- 1043-6618 (ISSN-L)
- OpenAlex
- W2916967884
- Cited by
- 308
- References
- 168
- FWCI
- 11.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.